They're probably going to use the MHRA ILAP pathway for their initial product while trialing the secondary one through the regular channels, that's how the pitch deck read to me anyways. I say they're on the market 1-3 years prior to Tsuji, without counting the commercial availability of later stage trials in Japan.It all depends if Stemson can utilise MHRA's ILAP pathway, and its been looking like they're going to attempt to go down that route for at least one of the products they try to commercialise.
While Tsuji may have a confirmed pathway to clinic, he hasn't got funding still (that we know) so its hard to believe that they're closer. A realistic expectation is confirmation of a partnership this year for Tsuji and co IMO.
This is assuming the process actually works, of course.